Enabling happier and healthier lives.
Our vision
Humankind is still suffering from diseases that are considered incurable.
We design and discover medicines for these incurable diseases through event-driven pharmacology by exploiting AI to design proximity-inducing compounds (PICs™).
We envision a society where patients and physicians have precise control of pathogenic human protein concentrations via small molecules.

Our mission
Our mission is to bring multiple first-in-class small molecule PICs™ to market as drugs against hard-to-drug targets by 2035.
PICs™ induce proximity to cellular degradation machinery and require a deep understanding of chemistry and biology to be successfully developed. PICs™ are optimized for their physicochemical properties and offer distinct advantages for therapeutic development, such as oral bioavailability and permeability.
We developed our CelerisTx One™ platform to design such drugs and to rationally improve them in a closed-loop.
Our platform is a holistic solution to design the components necessary to induce protein proximity. CelerisTx One™ automates subsequent chemical and biological tasks before proceeding through multiple design-make-test iterations to develop medicines for high unmet medical needs.
Driven by people.
Team



DI Christopher Trummer
CEO, Co-Founder and President
Jakob Hohenberger
CFO/COO, Co-Founder and Director
Dr. Markus Müllner
CSO

Christopher Trummer
CEO and Co-Founder

Jakob Hohenberger
CFO/COO and Co-Founder

Dr. Markus Müllner
CSO

Noah Weber
CTO

Noah Weber
CTO




Alexandra Moik
Research Scientist
Dr. Arjun Rao
Senior ML Researcher
Dr. Oskar Hoff
Head of Medicinal Chemistry
Dr. Michael Brunsteiner
Principal Scientist Comp. Chemistry

Alexandra Moik

Dr. Arjun Rao

Dr. Oskar Hoff

Dr. Michael Brunsteiner




Dr. Honorine Lebraud
Business Development Manager
Chiara Gasbarri
Computational Chemist
Tatjana Hirschmugl
Scientific Illustrations and Arts
Dr. Sagar Gore
CADD Researcher

Dr. Honorine Lebraud

Chiara Gasbarri, MSc.

Tatjana Hirschmugl, MSc.

Dr. Sagar Gore




Sara Weiß
Finance and Operations
Tin Tunjic
ML Engineer
Dr. Alzbeta Tuerkova
Head of CADD
Christina Hetzmannseder
Research Scientist

Sara Weiß

Tin Tunjic

Dr. Alzbeta Tuerkova

Christina Hetzmannseder


Dr. Krisztian Gal
Project Manager
Dr. Sridhar Radhakrishnan
Medicinal Chemist

Dr. Krisztian Gal

Dr. Sridhar Radhakrishnan
Dr. Sagar Gore
Board of Directors



Marius Swart
Board Director
Karel Kubias
Board Director
Dr. Peter Ho
Board Director


Dr. Ronjon Nag
Board Observer and Advisor
Petr Sramek
Board Observer and Advisor

Marius Swart
Board Director

Karel Kubias
Board Director

Dr. Peter Ho
Board Director

Petr Sramek
Board Observer and Advisor

Dr. Ronjon Nag
Board Observer and Advisor
Scientific Advisory Board





Assoc.-Prof. Dr. Johannes Kirchmair
University of Vienna
Computational Drug Discovery & Design Group
Prof. Dr. Ola Spjuth
University of Uppsala
Pharmaceutical Biosciences and Bioinformatics
Prof. Dr. Jean-Louis Reymond
University of Bern
Chemistry and Drug Design
Prof. Dr. David Selwood
University College London
Biological and Medicinal Chemistry
Prof. Dr. Stefan Knapp
Goethe University Frankfurt
Pharmaceutical Chemistry

Assoc.-Prof. Dr. Johannes Kirchmair
University of Vienna
Computational Drug Discovery & Design Group

Prof. Dr. Ola Spjuth
University of Uppsala
Pharmaceutical Biosciences and Bioinformatics

Prof. Dr. Jean-Louis Reymond
University of Bern
Chemistry and Drug Design

Prof. Dr. David Selwood
University College London
Biological and Medicinal Chemistry

Prof. Dr. Stefan Knapp
Goethe University Frankfurt
Pharmaceutical Chemistry